Celldex Therapeutics Inc. upsized its underwritten public offering by pricing 12 million shares of common stock at $7.50 – less than a 2 percent discount to Tuesday's close and a 1 percent premium to Monday's close – to seek a $90 million raise rather than $75 million cited in a preliminary prospectus filed Monday with the SEC. Read More
Derma Sciences Inc., of Princeton, N.J., is taking an important step in development of a therapy for a tough indication – diabetic foot ulcer. It began enrolling patients in the first of two Phase III trials of its topical drug candidate, DSC127. Read More
Studying cancer cells that survive chemotherapy treatment, scientists from Roche AG subsidiary Genentech Inc. have implicated a member of the human epidermal growth factor receptor, or HER, family in such treatment resistance. Read More
Whether the nation's budgetary glass for the next few years is half empty or half full is more a question of "ifs," rather than perspective, according to the Congressional Budget Office's (CBO) latest outlook for fiscal 2013-2023. A number of those ifs depend, to some extent, on health care spending. Read More
• Oxygen Biotherapeutics Inc., of Morrisville, N.C., said it signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research at Fort Sam Houston, Texas, to explore the potential effects of the firm's perfluorocarbon-based emulsion, Oxycyte, on platelet function and blood hemostasis. Read More
• Seattle Genetics Inc., of Bothell, Wash, said it started two Phase I trials of SGN-CD19A, which uses the firm's antibody-drug conjugate technology. Both are open-label, dose-escalation trials, one in B-cell acute lymphoblastic leukemia and the other in B-cell non-Hodgkin's lymphomas, and both are designed to assess the safety and antitumor activity of the CD19-targeted drug. Read More
• Celladon Corp., of San Diego, was issued a notice of allowance for U.S. Patent application No. 13/145,787, "Fluorescence resonance energy transfer assays for sarco/endoplasmic reticulum calcium ATPase and phosphlamban." Read More
